|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
92,610,000 |
Market
Cap: |
2.04(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$15.07 - $31.94 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. Co. has three clinical-stage ex vivo lentiviral vector. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,355,932 |
Total Buy Value |
$0 |
$0 |
$0 |
$19,999,997 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
418,173 |
438,811 |
467,219 |
487,632 |
Total Sell Value |
$11,574,225 |
$12,042,227 |
$12,602,151 |
$12,990,263 |
Total People Sold |
7 |
7 |
7 |
8 |
Total Sell Transactions |
12 |
14 |
24 |
29 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Schwartz Jonathan David |
See Remarks |
|
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
172,413 |
|
-18% |
|
Militello John |
See Remarks |
|
2024-03-21 |
4 |
S |
$28.10 |
$69,979 |
D/D |
(2,490) |
55,239 |
|
20% |
|
Makker Gotham |
|
|
2024-03-21 |
4 |
S |
$28.43 |
$7,790,943 |
I/I |
(274,000) |
365,912 |
|
20% |
|
Militello John |
See Remarks |
|
2024-02-29 |
4 |
S |
$29.85 |
$298,450 |
D/D |
(10,000) |
21,517 |
|
25% |
|
Militello John |
See Remarks |
|
2024-02-29 |
4 |
OE |
$12.55 |
$125,500 |
D/D |
10,000 |
31,517 |
|
- |
|
Wilson Martin |
General Counsel |
|
2024-02-29 |
4 |
S |
$29.33 |
$120,257 |
D/D |
(4,100) |
18,680 |
|
25% |
|
Patel Kinnari |
See Remarks |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
33,288 |
271,634 |
|
- |
|
Patel Kinnari |
See Remarks |
|
2024-02-16 |
4 |
S |
$29.84 |
$212,805 |
D/D |
(7,132) |
238,346 |
|
26% |
|
Shah Gaurav |
CEO |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
66,577 |
621,339 |
|
- |
|
Shah Gaurav |
CEO |
|
2024-02-16 |
4 |
S |
$29.84 |
$604,876 |
D/D |
(20,272) |
554,762 |
|
26% |
|
Militello John |
See Remarks |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,322 |
21,517 |
|
- |
|
Militello John |
See Remarks |
|
2024-02-16 |
4 |
S |
$29.84 |
$96,615 |
D/D |
(3,238) |
13,195 |
|
26% |
|
Wilson Martin |
General Counsel |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
16,644 |
22,780 |
|
- |
|
Wilson Martin |
General Counsel |
|
2024-02-16 |
4 |
S |
$29.84 |
$106,701 |
D/D |
(3,576) |
6,136 |
|
26% |
|
White Mark Andrew |
Chief Medical Officer |
|
2024-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
11,096 |
87,758 |
|
- |
|
Militello John |
See Remarks |
|
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,274 |
16,433 |
|
- |
|
Patel Kinnari |
See Remarks |
|
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,189 |
245,478 |
|
- |
|
Wilson Martin |
General Counsel |
|
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,712 |
9,712 |
|
- |
|
Shah Gaurav |
CEO |
|
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,828 |
575,034 |
|
- |
|
Militello John |
See Remarks |
|
2024-01-22 |
4 |
S |
$27.20 |
$17,356 |
D/D |
(638) |
10,159 |
|
21% |
|
Militello John |
See Remarks |
|
2024-01-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,586 |
10,797 |
|
- |
|
Makker Gotham |
|
|
2023-11-15 |
4 |
S |
$22.53 |
$450,646 |
I/I |
(20,000) |
1,296,497 |
|
-25% |
|
Militello John |
See Remarks |
|
2023-11-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
725 |
9,485 |
|
- |
|
Patel Kinnari |
See Remarks |
|
2023-11-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,989 |
220,437 |
|
- |
|
Shah Gaurav |
CEO |
|
2023-11-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,979 |
532,833 |
|
- |
|
66 Records found
|
|
Page 1 of 3 |
|
|